Continue to Site

Drug Discovery and Development

Pfizer and Moderna COVID-19 vaccines 90% effective in real-world study

By |

COVID-19 therapies vaccines coronavirus

[Photo by Daniel Schludi on Unsplash]

A single dose of Pfizer or Moderna vaccine is about 80% effective at preventing COVID-19 infection at least two weeks after injection. The efficacy level rises to 90% two weeks after the second dose of either mRNA vaccine, according to a recent CDC study involving roughly 4,000 essential workers.

In contrast to the Phase 3 trials from Pfizer-BioNTech and Moderna, the CDC study analyzed vaccines’ ability to prevent COVID-19 infection. Study participants underwent weekly COVID-19 testing for 13 consecutive weeks.

Conversely, the Pfizer-BioNTech and Moderna Phase 3 trials sought to analyze their vaccines’ ability to prevent symptomatic COVID-19 disease. Participants in the Pfizer had to have at least one COVID-19 symptom before they received a SARS-CoV-2 test. Study volunteers in the Moderna trial had to have at least two systemic symptoms or one respiratory symptom such as cough to qualify for a test.

The CDC study, like those from Pfizer-BioNTech and Moderna, used reverse-transcriptase polymerase-chain-reaction (RT-PCR) testing to confirm infections.

In addition to administering weekly testing, the CDC study also monitored participants for COVID-19–related symptoms. The weekly testing regimen detected 58% of the total COVID-19 cases, while the study organizers detected the remaining 42% after the onset of COVID-19 symptoms.

The majority of PCR-confirmed infections were identified by weekly specimens (58.0%), whereas 42.0% were identified from samples collected at the onset of COVID-19–associated illness.

The study participants included healthcare workers, first responders and frontline workers in hospitality, delivery, retail and education. Workers in such fields are more likely to be exposed to the novel coronavirus than the general public. Participants were based in six states, including Arizona, Florida, Minnesota, Oregon, Texas and Utah.

Filed Under: Infectious Disease
Tagged With: , , , , , , , , ,
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Tell Us What You Think!

Related Articles Read More >

Search Drug Discovery & Development